Hong Kong · Delayed Price · Currency is HKD Innovent Biologics Company Description
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.
Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection).
In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services.
The company was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7,502 |
| CEO | De-Chao Yu |
Contact Details
Address: 168 Dongping Street Suzhou, 215123 China | |
| Phone | 86 512 6956 6088 |
| Website | innoventbio.com |
Stock Details
| Ticker Symbol | 1801 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4818G1010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. De-Chao Yu Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Hao Xi Ede | Executive Director and Fund Managing Partner |
| Qian Zhang | Chief Commercial Officer, General Manager and Executive Director |
| Dr. Kaisong Zhou Ph.D. | Chief Operating Officer |
| Zhengwei Song C.F.A. | Director of IR and Financial Strategy |
| Cong Ding J.D. | General Counsel |
| Blake Salisbury | Senior Vice President |
| Dr. Hui Zhou Ph.D. | Chief Research & Development Officer for Oncology |
| Dr. Samuel Suhua Zhang M.B.A., Ph.D. | Global Chief Business Officer |
| Dr. Raj Dhodda Ph.D. | Senior Vice President |